Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In their study of the effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction, the OASIS-6 (Organization for the Assessment of Strategies for Ischemic Syndromes) Trial Group1 reported higher bleeding rates in patients treated with placebo than in patients treated with fondaparinux. This finding is difficult to explain2 and may be due to one of the many cointerventions.
Hartig F, Eller P, Pechlaner C. Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarction. JAMA. 2006;296(17):2087-2089. doi:10.1001/jama.296.17.2087-a